Biodexa Pharmaceuticals Overview
- Year Founded
-
2000
- Status
-
Public
- Employees
-
11
- Stock Symbol
-
BDRX
- Investments
-
4
- Share Price
-
$0.03
- (As of Friday Closing)
Biodexa Pharmaceuticals General Information
Description
Developer of biopharmaceutical products intended for the treatment of diseases with unmet medical needs. The company offers oral drug formulations, kinase modulators, molecular glue therapies, cancer therapeutics, diabetes therapeutics, brain cancer treatments, gastrointestinal tumor treatments, clinical-stage drug candidates, and drug delivery technologies, enabling the support of the development of treatments for diseases with high unmet medical needs.
Contact Information
Website
www.biodexapharma.comCorporate Office
- 1 Caspian Point
- Caspian Way
- Cardiff CF10 4DQ
- Wales, United Kingdom
Corporate Office
- 1 Caspian Point
- Caspian Way
- Cardiff CF10 4DQ
- Wales, United Kingdom
Biodexa Pharmaceuticals Timeline
Biodexa Pharmaceuticals Stock Performance
As of 05-May-2023, Biodexa Pharmaceuticals’s stock price is $0.03. Its current market cap is $4.21M with 94.6M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.03 | $0.04 | $0.03 - $3.04 | $4.21M | 94.6M | 200.00 | -$23.6K |
Biodexa Pharmaceuticals Financials Summary
As of 30-Jun-2026, Biodexa Pharmaceuticals has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 474 |
| EBITDA | (5,610) | (8,114) | (7,318) | (9,005) |
| Net Income | (5,931) | (8,409) | (7,320) | (8,799) |
| Total Assets | 16,859 | 24,480 | 18,546 | 13,429 |
| Total Debt | 0 | 82 | 912 | 591 |
Biodexa Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Biodexa Pharmaceuticals Comparisons
Industry
Financing
Details
Biodexa Pharmaceuticals Competitors (89)
One of Biodexa Pharmaceuticals’s 89 competitors is Pharmacyclics, a Venture Capital-Backed company based in San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Pharmacyclics | Venture Capital-Backed | San Francisco, CA | ||||
| Apexian Pharmaceuticals | Venture Capital-Backed | Indianapolis, IN | ||||
| Peptron | Formerly VC-backed | Daejeon, South Korea | ||||
| Cristal Therapeutics | Venture Capital-Backed | Maastricht, Netherlands | ||||
| AnTolRx | Formerly VC-backed | Cambridge, MA |
Biodexa Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Biodexa Pharmaceuticals Patents
Biodexa Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202212457-D0 | Metabolic interference | Inactive | 26-Aug-2022 | ||
| AU-2019395852-A1 | Antifolate-carrying nanoparticles and their use in medicine | Inactive | 14-Dec-2018 | ||
| CA-3123351-A1 | Antifolate-carrying nanoparticles and their use in medicine | Pending | 14-Dec-2018 | ||
| EP-3893938-A1 | Antifolate-carrying nanoparticles and their use in medicine | Inactive | 14-Dec-2018 | ||
| GB-201820470-D0 | Antifolate-carrying nanoparticles and their use in medicine | Inactive | 14-Dec-2018 | A61K47/6929 |
Biodexa Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Biodexa Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Biodexa Pharmaceuticals Investments & Acquisitions (4)
Biodexa Pharmaceuticals’s most recent deal was a Corporate Asset Purchase with Adhera Therapeutics (Worldwide License to Tolimidone). The deal was made on 21-Dec-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Adhera Therapeutics (Worldwide License to Tolimidone) | 21-Dec-2023 | Corporate Asset Purchase | Buildings and Property | ||
| Zuplenz | 30-Dec-2015 | Corporate Asset Purchase | Buildings and Property | ||
| Fortovia Therapeutics | 04-Dec-2015 | Merger/Acquisition | Pharmaceuticals | ||
| Medtech Pharma (Wales) | 08-Dec-2014 | Merger/Acquisition | Biotechnology |
Biodexa Pharmaceuticals ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Biodexa Pharmaceuticals Exits (1)
Biodexa Pharmaceuticals’s most recent exit was on 04-Dec-2015 from Fortovia Therapeutics. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Fortovia Therapeutics | 04-Dec-2015 | Completed |
|
Biodexa Pharmaceuticals Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Medtech Pharma (Wales) | Cardiff, United Kingdom | 2003 |
Biodexa Pharmaceuticals FAQs
-
When was Biodexa Pharmaceuticals founded?
Biodexa Pharmaceuticals was founded in 2000.
-
Where is Biodexa Pharmaceuticals headquartered?
Biodexa Pharmaceuticals is headquartered in Cardiff, United Kingdom.
-
What is the size of Biodexa Pharmaceuticals?
Biodexa Pharmaceuticals has 11 total employees.
-
What industry is Biodexa Pharmaceuticals in?
Biodexa Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Biodexa Pharmaceuticals a private or public company?
Biodexa Pharmaceuticals is a Public company.
-
What is Biodexa Pharmaceuticals’s stock symbol?
The ticker symbol for Biodexa Pharmaceuticals is BDRX.
-
What is the current stock price of Biodexa Pharmaceuticals?
As of 05-May-2023 the stock price of Biodexa Pharmaceuticals is $0.03.
-
What is the current market cap of Biodexa Pharmaceuticals?
The current market capitalization of Biodexa Pharmaceuticals is $4.21M.
-
Who are Biodexa Pharmaceuticals’s competitors?
Pharmacyclics, Apexian Pharmaceuticals, Peptron, Cristal Therapeutics, and AnTolRx are some of the 89 competitors of Biodexa Pharmaceuticals.
-
What is Biodexa Pharmaceuticals’s annual earnings per share (EPS)?
Biodexa Pharmaceuticals’s EPS for 12 months was -$23.6K.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
